Results 211 to 220 of about 325,525 (350)

Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab

Hepatology Research, EarlyView.
ABSTRACT Background Conversion therapy, which seeks to achieve curative treatment following systemic therapy, is increasingly acknowledged in the management of unresectable hepatocellular carcinoma (HCC). However, validated criteria for predicting eligibility for conversion remain unclear. We investigated the utility of the recently proposed borderline
Yasuto Takeuchi, Masahiko Sue, Nozomi Miyake, Takuya Adachi, Hideki Onishi, Miwa Kawanaka, Akinobu Takaki, Kazuhiro Nouso, Kazuya Kariyama, Shinichiro Nakamura, Emi Tanaka, Toshifumi Tada, Tetsuya Yasunaka, Kenji Kuwaki, Junichi Toshimori, Shota Iwado, Akio Moriya, Hiroaki Hagihara, Hiroyuki Takabatake, Masahiro Sakata, Motoyuki Otsuka   +20 more
wiley   +1 more source

Challenges of Hepatitis B Virus Reactivation and CD19 Testing Following Tafasitamab Plus Lenalidomide for Relapsed Diffuse Large B-Cell Lymphoma. [PDF]

J Med Cases
Yu TC, Chou WC.
europepmc   +1 more source

Incidence and Characteristics of HBV Reactivation‐Related Events Following HBsAg Seroclearance: Long‐Term Follow‐up of a Population‐Based Cohort in Japan

Hepatology Research, EarlyView.
In a population‐based cohort in Japan, HBV reactivation‐related events were observed after HBsAg seroclearance, including one virologically confirmed hepatic flare occurring spontaneously without chemotherapy or immunosuppression. These findings indicate that HBsAg seroclearance does not always represent complete viral eradication, supporting the need ...
Kazumi Yamasaki, Satoshi Shirahama, Takahiro Yasaka, Shota Yamaguchi, Masashi Mizokami, Junko Tanaka, Hiroaki Okamoto, Hiroshi Yatsuhashi   +7 more
wiley   +1 more source

Hepatitis B Core-Related Antigen Level Predicts Disease Progression in the Gray Zone Hepatitis B Patients. [PDF]

J Med Virol
Suzuki T, Matsuura K, Inoue T, Kawamura H, Fujiwara K, Kataoka H, Tanaka Y.   +6 more
europepmc   +1 more source

VEGF‐Positive Mass‐Forming Intrahepatic Cholangiocarcinoma: New Subtype Based on Radiological and Molecular Pathological Analysis

Hepatology Research, EarlyView.
Radiological and molecular pathological investigation of hypervascular intrahepatic cholangiocarcinoma, typically a hypovascular tumor, revealed high VEGF expression, an increase in tumor‐associated arterial vessels, and a strong correlation with favorable prognosis.
Junya Tsuzaki, Naoto Kubota, Shigeyoshi Soga, Yasuhito Arai, Tatsuhiro Shibata, Minoru Esaki, Masahiro Jinzaki, Hidenori Ojima   +7 more
wiley   +1 more source

Human Islet

Cell Proliferation, EarlyView.
Jiaqi Zou, Shen Li, Hongxing Fu, Mei Zhang, Anbin Hu, Xiaohui Tian, Yuanyuan Du, Lingling Wei, Xuchun Chen, Jie Gao, Rui Liang, Xinshun Feng, Yang Li, Ying Wang, Xiangheng Cai, Peng Sun, Xuejie Ding, Boya Zhang, Tengli Liu, Na Liu, Jie Hao, Lei Wang, Hongling Zhao, Jiani Cao, Aijin Ma, Lijun Zhu, Qiyuan Li, Qiang Wei, Xiaoming Ding, Ying Cheng, Tongbiao Zhao, Shusen Wang   +31 more
wiley   +1 more source

Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd‐EOB‐DTPA‐MRI

Hepatology Research, EarlyView.
Hepatocellular carcinoma (HCC) is a common type of liver cancer. Recently, combination therapy with atezolizumab plus bevacizumab has become a standard systemic treatment for patients with unresectable HCC. Some HCCs show high signal intensity on the hepatobiliary phase of Gd‐EOB‐DTPA–enhanced MRI.
Tomoko Aoki, Masatoshi Kudo, Kazuomi Ueshima, Masakatsu Tsurusaki, Keitaro Sofue, Yoshihiko Yano, Hidenori Toyoda, Atsushi Hiraoka, Takeshi Hatanaka, Atsushi Naganuma, Satoru Kakizaki, Norio Itokawa, Masanori Atsukawa, Kazuhito Kawata, Kazuto Tajiri, Joji Tani, Toru Ishikawa, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Takashi Kumada, Naoshi Nishida, Yuzo Kodama   +24 more
wiley   +1 more source

Comment on "A single-cell digital PCR method tailored for quantification of HBV DNA positive cells in liver biopsy tissues". [PDF]

J Transl Med
Chen Y, Zhao G, Song J.
europepmc   +1 more source

HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant.

Gastroenterology, 2016
W. Mason, U. Gill, S. Litwin, Yan Zhou, S. Peri, O. Pop, M. Hong, S. Naik, A. Quaglia, A. Bertoletti, P. Kennedy   +10 more
semanticscholar   +1 more source

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Hepatology Research, EarlyView.
ABSTRACT Aim Systemic therapy is required for unresectable hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab (ATZ/BEV) is the recommended first‐line treatment for HCC; however, the development of anti‐drug antibodies (ADAs) against ATZ may impair its therapeutic efficacy. Although ADAs have been reported in other cancers treated with immune
Keishi Ouchi, Jun Inoue, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Kotaro Doi, Kengo Watanabe, Tomoya Sasazaki, Atsushi Masamune   +8 more
wiley   +1 more source